Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 08, 2026 07:00 ET | Source: Incyclix Bio

Incyclix Bio Raises Additional $5 Million in Series B Financing to Advance Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors

RESEARCH TRIANGLE PARK, N.C., April 08, 2026 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for...
September 14, 2020 07:00 ET | Source: G1 Therapeutics

G1 Therapeutics to Present Data on Oral CDK4/6 Inhibitor Lerociclib at European Society for Medical Oncology (ESMO) Virtual 2020 Congress

RESEARCH TRIANGLE PARK, N.C., Sept. 14, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that two presentations highlighting data on...